8-K 1 v460053_8k.htm 8-K




Washington, D.C. 20549






Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): February 17, 2017



(Exact name of registrant as specified in its charter)



(State or other jurisdiction

of incorporation)


(Commission File Number)


(IRS Employer

Identification No.)


205 East 42nd Street, 16th Floor
New York, New York 10017
(Address of principal executive offices and zip code)


Registrant’s telephone number, including area code: (973) 242-0005 


(Former Name or Former Address, if Changed Since Last Report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))






 Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On February 17, 2017, upon the recommendation of the Nominating and Governance Committee of the board of directors (the “Board”) of Neurotrope, Inc. (the “Company”), the Board appointed Andrew D. Perlman as a member of the Board, effective immediately, to hold office until the next annual meeting of the stockholders of the Company, until his successor is duly elected and qualified, or until his resignation or removal. Effective February 17, 2017, Mr. Perlman was appointed to serve as a member of the Audit Committee of the Board. Consistent with the Company’s standard compensation arrangements for non-employee directors, Mr. Perlman will receive an option to purchase, at an exercise price equal to the price at which the Company’s common stock closes on February 17, 2017, as reported by the OTCQB, up to (i) 7,813 shares of the Company’s common stock for his service to the Company as a non-employee director and (ii) 1,563 shares of the Company’s common stock for his service to the Company as a committee member, each such grant to vest in equal daily installments over a five-year period beginning on the date of grant. The options are granted subject to stock option agreements to be entered into by and between the Company and Mr. Perlman evidencing the granting of the options, substantially in the form of the Company’s standard form of stock option. There are no arrangements or understandings between Mr. Perlman and any other person pursuant to which he was selected as a director. The Company is not aware of any transaction in which Mr. Perlman has an interest requiring disclosure under Item 404(a) of Regulation S-K.







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: February 22, 2017 By: /s/ Robert Weinstein
  Name: Robert Weinstein
  Title: Chief Financial Officer, Executive Vice President, Secretary and Treasurer